Russia’s only project to supply local high-tech anti-cancer drugs abroad  continues with the first shipment to Vietnam

11.02.2016

Russia’s only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam

Russian biopharmaceutical company BIOCAD is the first company in the country to launch a 150-million-dollar effort to supply therapeutic products based on monoclonal antibodies to several countries outside Russia. In the end of December BIOCAD made its first shipment to Vietnam.

More Category: Media release
BIOCAD - World Leader in Biosimilar Rituximab Sales

22.10.2015

BIOCAD - World Leader in Biosimilar Rituximab Sales

Biopharmaceutical company BIOCAD is now the world leader in sales of biosimilar rituximab. Company revenue from sales of Acellbia™, exceeded $155 million in 2014, representing more than 80% of global sales of non-originator rituximab biologicals.

More Category: Media release
Supplies of Russian anti-cancer drug into Egypt will amount to $42.7 million

08.09.2015

Supplies of Russian anti-cancer drug into Egypt will amount to $42.7 million

On September 3, 2015 in St. Petersburg, Russia, an agreement was signed between a Russian innovative biotech company BIOCAD and the Egyptian company MED. PHARMA GROUP regarding supplies of anti-cancer drug Rituximab into Egypt.

More Category: News
200 million rubles in creation of new R&D

12.08.2015

200 million rubles in creation of new R&D

The biotechnological corporation BIOCAD has invested over 200 million rubles in creation of new R&D center in St. Petersburg area.

More Category: Media release
Nobel laureate James Watson visited BIOCAD

23.06.2015

Nobel laureate James Watson visited BIOCAD

James Watson, who won the 1962 Nobel Prize in Biology and Medicine for the discovery of three-dimensional molecular structure of DNA, on June 20 visited the laboratories of the innovative biotech company BIOCAD.

More Category: News